<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04124484</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC/HA1117/PRO-II</org_study_id>
    <nct_id>NCT04124484</nct_id>
  </id_info>
  <brief_title>DBPR108 Tablets in Type 2 Diabetes Mellitus Patients</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of DBPR108 Tablets for Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluate DRBP108 in the treatment of type 2 diabetes mellitus. The patients were
      randomly allocated to four groups: 50 mg, 100 mg, 200 mg and placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was to evaluate DRBP108 in the treatment of type 2 diabetes mellitus. A total of
      268 subjects were randomly allocated to four treatment arms: 50 mg, 100 mg, 200 mg or placebo
      group, in a 1:1:1:1 ratio.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">February 27, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBA1c</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>Changes in HbA1c compared to baseline at week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBA1c</measure>
    <time_frame>Baseline, week 8, week4</time_frame>
    <description>Changes in HbA1c compared to baseline at week 8, week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>Baseline, week 4，week 8, week 12</time_frame>
    <description>Changes in Fasting plasma glucose compared to baseline at week 4,week 8, week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hour postprandial plasma glucose</measure>
    <time_frame>Baseline, week 4，week 8, week 12</time_frame>
    <description>Changes in 2-hour postprandial plasma glucose compared to baseline at week 4,week 8, week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucagon</measure>
    <time_frame>Baseline, week 4，week 8, week 12</time_frame>
    <description>Changes in fasting glucagon compared to baseline at week 4,week 8, week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting Insulin</measure>
    <time_frame>Baseline, week 4，week 8, week 12</time_frame>
    <description>Changes in fasting Insulin compared to baseline at week 4,week 8, week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>active Glucagon-like peptide-1（GLP-1）</measure>
    <time_frame>Baseline, week 4，week 8, week 12</time_frame>
    <description>Changes in active（GLP-1）compared to baseline at week 4,week 8, week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of HbA1c≤6.5% or HbA1c≤7%</measure>
    <time_frame>week 12</time_frame>
    <description>The percentage of HbA1c≤6.5% or HbA1c≤7% at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
    <time_frame>Baseline, week 4，week 8, week 12</time_frame>
    <description>Changes in body weight（Kg）compared to baseline at week 4,week 8, week 12</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">276</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>50mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one 50mg of DBPR108 tablet and two placebos matching DBPR108 100mg under fasted conditions for one day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one 100mg of DBPR108 tablet and two placebos matching DBPR108 50mg and 100mg under fasted conditions for one day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two 100mg of DBPR108 tablets and one placebo matching DBPR108 50mg under fasted conditions for one day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received two placebo matching DBPR108 100mg and one placebo matching DBPR108 50mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)</intervention_name>
    <description>One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks</description>
    <arm_group_label>50mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)</intervention_name>
    <description>One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks</description>
    <arm_group_label>100mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)</intervention_name>
    <description>Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks</description>
    <arm_group_label>200mg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)</intervention_name>
    <description>Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who meet the World Health Organization(WHO) (1999) criteria for the diagnosis
             and classification criteria for type 2 diabetes;

          -  18 ≤ age ≤ 75 years old, male or female;

          -  One of the following conditions:

               1. Initial diagnosis of type 2 diabetes mellitus;

               2. Patients who with type 2 diabetes diagnosed within 2 years before screening
                  period and are treated with single-agent oral hypoglycemic agents until
                  screening, and do not take the medicine regularly for at least 8 weeks (i.e.,
                  continuous medication for &lt;1 week);

          -  19kg/m^2 ≤ Body Mass Index（BMI ）≤ 35kg/m^2;

          -  7.0% ≤ HbA1c ≤ 10.0%;

          -  Female subjects of childbearing age are negative in pregnancy test;

          -  All the subjects do not have a fertility plan during and three month after the trial;

          -  Subjects who fully understand the test content and possible adverse reactions and
             voluntarily participate in the trial and sign the informed consent form;

        Exclusion Criteria:

          -  FPG &gt; 15 mmol/L;

          -  Systolic blood pressure &gt; 160 mmHg or diastolic blood pressure &gt; 100 mmHg during
             screening period;

          -  Those who are known to be positive for HIV and syphilis;

          -  known active hepatitis B virus infection, hepatitis C virus infection;

          -  For patients with obvious liver diseases and chronic liver diseases, AST or ALT in
             screening stage was twice the normal upper limit.

          -  In patients with renal insufficiency, serum creatinine at screening stage was 1.5
             times higher than the upper limit of normal value;

          -  Leukocyte and hemoglobin &lt; lower limit of normal value, triglyceride &gt; 5.7 mmol/L in
             screening stage;

          -  With diabetic acute complications (including diabetic ketoacidosis, hypertonic
             non-ketoacid diabetic coma, lactic acidosis and hypoglycemic coma), chronic
             complications (proliferative diabetic retinopathy, diabetic nephropathy);

          -  Use of insulin, pioglitazone, DPP-4 inhibitor, GLP-1 receptor agonist or any
             combination of two or more oral hypoglycemic drugs within 8 weeks before screening
             time.

          -  Those who need insulin therapy;

          -  Using and Used of glucocorticoids within 2 weeks before screening time.

          -  without a pacemaker, the 12-lead ECG showed II or III degree atrioventricular block,
             long QT syndrome or corrected QT interval （QTc）&gt;500ms or atrial fibrillation during
             the screening period;

          -  History of epilepsy, mental illness, major depression, or previous thyroid function
             abnormal and still being treated, or those with organ transplants, severe chronic lung
             disease, and other serious heart disease, cerebrovascular disease, blood disease;

          -  Inflammatory bowel disease, colon ulcer, partial intestinal obstruction or chronic
             intestinal diseases associated with digestive and absorption diseases;

          -  Active pancreatitis, cholecystitis, gallstones and other digestive diseases;

          -  History of severe hypoglycemia;

          -  History of allergies with similar drugs (DPP-4 inhibitors) or those who are judged by
             the investigator to be allergic to the test drug;

          -  Pregnancy, lactating women;

          -  Subjects who are participating in other clinical trials or who have participated in
             other drug trials within 3 months prior to screening;

          -  Not suitable for this clinical trial judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>First Hospital of Peking Unversity</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>October 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2019</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DBPR108</keyword>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>DPP4 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

